Migraine

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

Retrieved on: 
Thursday, January 4, 2024
Migraine, Dextromethorphan/bupropion, Binge eating disorder, DSM-IV codes, NDA, Brain, MD, Therapy, Clinical trial, Solriamfetol, FOCUS, SYMPHONY, Fibromyalgia, CNS, Prescription, Central nervous system, Patient, ADHD, Narcolepsy, Somnolence, Pharmaceutical industry

“Axsome completed its first full year as a commercial company in 2023 and, during that time, our medicines reached approximately 100,000 unique patients.

Key Points: 
  • “Axsome completed its first full year as a commercial company in 2023 and, during that time, our medicines reached approximately 100,000 unique patients.
  • Auvelity® net product sales are expected to be approximately $49 million and $130 million for the fourth quarter and full year of 2023, respectively.
  • Sunosi® net product revenue is expected to be $22 million and $74 million for the fourth quarter and full year of 2023, respectively.
  • Net product revenue excludes $66 million in license revenue recognized by Axsome in the first quarter of 2023.

Pulsetto Unveils Groundbreaking Vagus Nerve Stimulation Device at CES

Retrieved on: 
Thursday, January 4, 2024
Cluster, Pain management, Philosophy, Cluster headache, Pain, Migraine, Periodicity, Neurostimulation, Vagus nerve stimulation, Sleep, Vagus nerve, CES, VNS, Relaxation, Neck

Pulsetto, a leader in Vagus Nerve Stimulation technology, is showcasing at CES its unique dual-technology system and personalized app designed to alleviate stress, reduce anxiety, improve sleep, and manage pain, exemplifying a practical and everyday approach to enhancing mental wellness.

Key Points: 
  • Klaipeda County, Lithuania--(Newsfile Corp. - January 4, 2024) - Pulsetto is set to showcase at CES in Las Vegas, bringing its effective Vagus Nerve Stimulation (VNS) device into the spotlight.
  • A pivotal moment came when he encountered an article about vagus nerve stimulation, sparking the idea for Pulsetto.
  • This device innovatively activates the vagus nerve, a key player in regulating stress responses in the body.
  • On this note, Pulsetto invites all CES attendees to booth 8867 for a hands-on experience with its transformative Vagus Nerve Stimulation device.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Retrieved on: 
Wednesday, January 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Kite Pharma, Engineering management, Tufts University, Marketing, Lilly, Migraine, Johnson & Johnson, Amgen, Sale, AstraZeneca, Daiichi Sankyo, Eli Lilly, Jan Vansina, Business administration, Engineering, WebMD, MBA, Chemical engineering, Doctor of Philosophy, Roivant Sciences, Therapy, Eli Lilly and Company, Consumer service, University, Washington State University, Worcester Polytechnic Institute, Iowa State University, SVP, Corporation, Pharmaceutical industry

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.

Key Points: 
  • ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
  • “We are delighted to welcome Christi Shaw, Mert Aktar and David Marek, and the tremendous expertise and wise counsel they represent, to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta's Board of Directors.
  • Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines.
  • Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience bridging science and business in pharmaceuticals and biotechnology.

Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor

Retrieved on: 
Wednesday, January 3, 2024
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Mental health service, Disease, Lilly, Dementia, CMA, Migraine, Multimedia, Mental health, Addiction, Pharmacy, Drug discovery, Eli Lilly, CMO, Pain, Depression, University, FRCP, Alzheimer's disease, Schizophrenia, University of Toronto, Anxiety, Therapy, DSM-IV codes, Pharmaceutical industry

Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor (CMA).

Key Points: 
  • Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor (CMA).
  • View the full release here: https://www.businesswire.com/news/home/20240103994981/en/
    Dr. Joel Raskin joins ArrivoBio as Chief Medical Advisor.
  • (Photo: Business Wire)
    “We are honored to welcome Dr. Joel Raskin to our team as we continue to advance our novel therapies SP-624 and RABI-767,” said Steve Butts, CEO of Arrivo.
  • Over the course of his career, Dr. Raskin has published nearly 100 scientific articles.

Is cold water bad for you? What about drinking from the hose or tap? The facts behind 5 water myths

Retrieved on: 
Tuesday, January 2, 2024
Lead, Myth II: Soulblighter, Water, Grain, Dysphagia, Woman, Mineral, Drinking, Glass, Dysentery, Esophageal achalasia, Health, Headache, Drinking water, Bacteria, Migraine, Life expectancy, Plant, University, Microplastics, River, Temperature, Metal, Public, Cholera, Fresh water, University of Queensland, Exercise, Environment, Bottled water

Myth 1: Cold water is bad for you

Key Points: 
  • Myth 1: Cold water is bad for you
    Some recent TikToks have suggested cold water causes health problems by somehow “contracting blood vessels” and “restricting digestion”.
  • Cold water after exercise in summer or hot water to relax in winter won’t make any difference to your overall health.
  • Hot water is generally a better solvent than cold water, so may dissolve metals and minerals from pipes better.
  • It’s better to fill your cup from the cold tap and get hot water for drinks from the kettle.

Premier Naturopathic Medical Practice, Nova Clinic, Moves To Roswell, GA, Location

Retrieved on: 
Tuesday, January 2, 2024
Patient, Senior counsel, Multimedia, National university, Chronic pain, Health, Diabetes, Outline of health sciences, Migraine, Metro Area, Emory University, Fertility, Anxiety, Biochemistry, Thyroid, ADD, Psychology, Nature, Pharmaceutical industry

ROSWELL, Ga., Jan. 2, 2024 /PRNewswire-PRWeb/ -- Nova Clinic, a leading naturopathic medical practice, is thrilled to announce its relocation to a state-of-the-art facility on January 1, 2024. The clinic's new address is 1240 Upper Hembree Rd., Suite E, and is conveniently located inside Vita Infusions in Roswell, Georgia. Under the guidance of esteemed naturopathic doctor, Dr. Shama Patel, Nova Clinic has gained a reputation for providing safe, natural and holistic therapies that prioritize patient well-being. The new location at 1240 Upper Hembree Rd., Suite E close to downtown Alpharetta, will allow Nova Clinic to better serve the community and meet the growing demand for alternative medicine. Patients can expect a warm and inviting atmosphere that promotes healing and wellness.

Key Points: 
  • ROSWELL, Ga., Jan. 2, 2024 /PRNewswire-PRWeb/ -- Nova Clinic, a leading naturopathic medical practice , is thrilled to announce its relocation to a state-of-the-art facility on January 1, 2024.
  • Under the guidance of esteemed naturopathic doctor, Dr. Shama Patel, Nova Clinic has gained a reputation for providing safe, natural and holistic therapies that prioritize patient well-being.
  • The new location at 1240 Upper Hembree Rd., Suite E close to downtown Alpharetta, will allow Nova Clinic to better serve the community and meet the growing demand for alternative medicine.
  • Dr. Patel is a member of the American Association of Naturopathic Physicians and the Georgia Association of Naturopathic Physicians.

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Retrieved on: 
Tuesday, December 26, 2023
Pain management, Contraindication, Migraine, Physician, FDA, Chronic pain, Headache, Nonsteroidal anti-inflammatory drug, Neurology, PALO, Health Canada, Patient, Therapy, NDS, Pharmaceutical industry

Clinicians in a recent market research study expressed their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use.

Key Points: 
  • Clinicians in a recent market research study expressed their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use.
  • ELYXYB®’s product profile mapped with a high degree of certainty to these stated unmet needs.
  • This is a highly complementary commercial asset that allows us to provide physicians with another tool in their pain management armamentarium to treat migraines earlier in the patient journey.
  • For more information on ELYXYB®, including Full Prescribing Information, please visit ELYXYB.com

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing

Retrieved on: 
Tuesday, December 19, 2023
Food, Risk, Migraine, Diarrhea, FDA, ACR, Gout, Chronic pain, Colchicine, PALO, American College, Pharmacy, Patient, Rheumatology, Pharmaceutical industry

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Key Points: 
  • Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
  • Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1.
  • As gout cases increase every year, treatment requirements increase.
  • The gout treatment market is projected to reach $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.2
    Over 17% of gout patients had gastrointestinal side effects like diarrhea.

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Retrieved on: 
Monday, December 18, 2023
Risk, Migraine, Zygomatic bone, Grammatical mood, Forehead, Depression, Capital Medical University, Trial of the century, Clinical trial, Behavior, Appetite, Sleep, MDD, Patient, TRD, Pharmaceutical industry

The published results of the study concluded that repeated treatment with Nexalin’s neurostimulation device suggests an acute effect in reducing depressive symptoms in patients with TRD.

Key Points: 
  • The published results of the study concluded that repeated treatment with Nexalin’s neurostimulation device suggests an acute effect in reducing depressive symptoms in patients with TRD.
  • Major depressive disorder (MDD), also known as clinical depression, is a mental health condition that affects mood, behavior, appetite, and sleep.
  • We believe the data provides further evidence of the significant impact of our non-invasive, drug-free device on improving mental healthcare outcomes among patients affected with TRD.
  • No significant adverse effects were reported, which is especially noteworthy given the growing number of patients seeking non-pharmacological treatment options.

Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch

Retrieved on: 
Monday, December 18, 2023
MAP, Marketing, Food, Intellectual property, Migraine, FDA, Acquisition, NDA, Record, New Drug Application, Food and Drug Administration, Vaccine

This transfer from the former California-based Zosano Pharma Corporation (Fremont, CA) follows the acquisition of Zosano operating assets by Emergex.

Key Points: 
  • This transfer from the former California-based Zosano Pharma Corporation (Fremont, CA) follows the acquisition of Zosano operating assets by Emergex.
  • Emergex also notified the FDA of an extension of Zosano’s submission of epidermal migraine treatment patch NDA for potential marketing authorization.
  • The extension will allow Emergex to continue manufacturing the epidermal delivery patch with its own pipeline of T cell-priming candidates.
  • We now have a highly sophisticated vaccine platform paired with a pragmatic delivery tool, which we believe makes a recipe for success.”